Mackenzie Financial Corp Alkermes Plc. Transaction History

Mackenzie Financial Corp

$77.1 Billion
Q3 2025

A detailed history of Mackenzie Financial Corp transactions in Alkermes Plc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 442,350 shares of ALKS stock, worth $12.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

442,350

Previous 290,327 52.36%

Holding current value

$12.8 Million

Previous $8.31 Million 59.76%

% of portfolio

0.02%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$26.13 - $30.46 $3.97 Million - $4.63 Million	152,023 Added 52.36%	442,350 $13.3 Million
Q2 2025 Aug 13, 2025	BUY	$26.59 - $32.65 $1.42 Million - $1.74 Million	53,323 Added 22.5%	290,327 $8.31 Million
Q1 2025 May 07, 2025	SELL	$28.08 - $36.0 $2.69 Million - $3.44 Million	-95,622 Reduced 28.75%	237,004 $7.83 Million
Q4 2024 Feb 14, 2025	BUY	$25.7 - $31.46 $709,422 - $868,421	27,604 Added 9.05%	332,626 $9.57 Million
Q3 2024 Nov 13, 2024	BUY	$23.01 - $28.55 $1 Million - $1.25 Million	43,618 Added 16.69%	305,022 $8.54 Million

Q2 2024 Aug 14, 2024	SELL	$23.21 - $27.24 $146,408 - $171,829	-6,308 Reduced 2.36%	261,404 $6.3 Million
Q1 2024 May 10, 2024	BUY	$26.4 - $32.56 $3.58 Million - $4.41 Million	135,460 Added 102.43%	267,712 $7.25 Million
Q4 2023 Jan 30, 2024	BUY	$23.37 - $28.68 $234,330 - $287,574	10,027 Added 8.2%	132,252 $3.67 Million
Q3 2023 Oct 25, 2023	BUY	$27.17 - $31.97 $1.35 Million - $1.58 Million	49,561 Added 68.21%	122,225 $3.42 Million
Q2 2023 Aug 03, 2023	BUY	$28.34 - $33.63 $1.71 Million - $2.03 Million	60,472 Added 496.0%	72,664 $2.27 Million
Q1 2023 Apr 24, 2023	BUY	$25.31 - $29.02 $308,579 - $353,811	12,192 New	12,192 $343,000
Q3 2022 Oct 07, 2022	SELL	$22.0 - $31.87 $44,902 - $65,046	-2,041 Reduced 2.57%	77,460 $1.73 Million
Q2 2022 Aug 10, 2022	BUY	$26.4 - $30.54 $1.84 Million - $2.12 Million	69,544 Added 698.44%	79,501 $2.37 Million
Q1 2022 May 13, 2022	SELL	$23.07 - $27.99 $22,400 - $27,178	-971 Reduced 8.89%	9,957 $262,000
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $35,081 - $52,418	1,634 Added 17.58%	10,928 $254,000
Q3 2021 Nov 08, 2021	BUY	$23.37 - $32.13 $217,200 - $298,616	9,294 New	9,294 $287,000
Q1 2021 May 14, 2021	SELL	$18.21 - $23.2 $219,430 - $279,560	-12,050 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$15.39 - $22.1 $185,449 - $266,305	12,050 New	12,050 $240,000
Q3 2018 Nov 15, 2018	SELL	$38.6 - $46.12 $283,671 - $338,935	-7,349 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$40.56 - $51.36 $184,426 - $233,533	-4,547 Reduced 38.22%	7,349 $302,000
Q1 2018 May 14, 2018	BUY	$53.61 - $67.26 $192,352 - $241,328	3,588 Added 43.19%	11,896 $689,000
Q4 2017 Feb 13, 2018	BUY	$47.69 - $55.39 $150,795 - $175,143	3,162 Added 61.45%	8,308 $455,000
Q3 2017 Nov 13, 2017	BUY	$49.16 - $54.45 $20,253 - $22,433	412 Added 8.7%	5,146 $262,000
Q2 2017 Aug 14, 2017	BUY	N/A	4,734	4,734 $274,000

Others Institutions Holding ALKS

# of Institutions

401

Shares Held

176M

Call Options Held

901K

Put Options Held

400K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.77B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account

Mackenzie Financial Corp Alkermes Plc. Transaction History